Immuneering (IMRX) Leases: 2020-2024
Historic Leases for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to $3.7 million.
- Immuneering's Leases fell 8.21% to $3.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.7 million, marking a year-over-year decrease of 8.21%. This contributed to the annual value of $4.0 million for FY2023, which is 9.35% down from last year.
- According to the latest figures from Q3 2024, Immuneering's Leases is $3.7 million, which was down 2.07% from $3.8 million recorded in Q2 2024.
- Over the past 5 years, Immuneering's Leases peaked at $5.3 million during Q4 2021, and registered a low of $537,181 during Q3 2021.
- For the 3-year period, Immuneering's Leases averaged around $4.2 million, with its median value being $4.2 million (2023).
- In the last 5 years, Immuneering's Leases skyrocketed by 768.40% in 2021 and then dropped by 17.21% in 2022.
- Quarterly analysis of 5 years shows Immuneering's Leases stood at $613,103 in 2020, then skyrocketed by 768.40% to $5.3 million in 2021, then dropped by 17.21% to $4.4 million in 2022, then decreased by 9.35% to $4.0 million in 2023, then fell by 8.21% to $3.7 million in 2024.
- Its Leases stands at $3.7 million for Q3 2024, versus $3.8 million for Q2 2024 and $3.9 million for Q1 2024.